Skip to main content
Premium Trial:

Request an Annual Quote

Charles Vest Dies

Charles Vest, the former president of the Massachusetts Institute of Technology and science advocate, has died, ScienceInsider reports. He was 72.

Vest served as president at MIT from 1990 to 2004, a time, the New York Times notes, was marked by increased effort and funds for the life sciences, nanotechnology, and media. He also over saw the introduction of the OpenCourseWare project that allowed users to take MIT courses online.

Additionally, the Times writes that Vest worked to include women and minorities in leadership positions at the school.

"Chuck Vest was both a product and a champion of this nation’s powerful scientific and engineering community," former US President Bill Clinton says in a statement at the MIT website. "He served with distinction as an ambassador and spokesman for science in Washington, advocating tirelessly for the essential role of research in our economic growth and national security."

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.